Date: August 27, 2026
Venue: Sonesta Philadelphia Rittenhouse Hotel, Philadelphia, PA
Professionals and executives from clinical, legal, regulatory, and operational sectors are invited to attend the 7th Clinical Trial Agreements Summit, to be held on Aug. 27-28, 2026, at the Sonesta Philadelphia Rittenhouse Hotel in Philadelphia, Pennsylvania.
The event is hosted by Dynamic Global Events (“DGE”), a world leader in curating b2b events for life science companies. The summit aims to guide stakeholders in navigating the complex landscape of clinical trial agreements (“CTAs”), as they adapt to new regulations, technologies, and best practices.
Why attend?
- Industry experts will explore practical strategies for addressing the challenges in clinical trial contracting, such as decentralized trial operations, global data transfer requirements, cybersecurity considerations, post-trial access planning, and inspection readiness.
- Gain practical guidance for negotiating budgetary constraints, protecting intellectual property and clinical data, and reducing risks related to indemnification and subject injury.
- Attendees will also gain insights into regulatory developments and emerging trends that may affect future clinical research agreements
- The event is expected to attract professionals from clinical contracts, legal affairs, clinical operations, compliance, regulatory affairs, corporate counsel, clinical development, medical affairs, and related disciplines.
- Participants can utilize this platform to connect with industry experts, exchange ideas, and expand their professional networks through educational sessions and interactive discussions.
Some key topics of discussion among industry leaders will include negotiation strategies, intellectual property protection, clinical data considerations, and risk mitigation approaches. The summit aims to provide attendees with actionable knowledge that can help streamline agreement processes and support more efficient clinical trial activation.
To learn more, please visit https://ibn.fm/fGgEH.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN